Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SUPN SUPERNUS PHARMACEUTICALS, INC. 8-K

Supernus schedules Q1 2026 earnings release for May 5 after market close

Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read

1 key change 2 sections

Key Changes

  • low

    Company will report first quarter 2026 financial and business results after market close on Tuesday, May 5, 2026, followed by a conference call and webcast at 4:30 p.m. ET with CEO Jack Khattar and CFO Tim Dec.

    Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →

Summary

Supernus Pharmaceuticals filed a routine scheduling announcement for its first quarter 2026 earnings release. The company will report financial and business results after the market closes on Tuesday, May 5, 2026, with management hosting a conference call and webcast at 4:30 p.m. ET the same day to discuss the results.

This is a standard procedural filing with no financial results disclosed. Retail investors should mark their calendars for May 5 to review the company's quarterly performance when the actual results are released.

Section-by-Section Diff

Event · Exhibit 99.1

2 Added
Show 2 minor / wording changes
Added Q1 2026 earnings announcement low

Added in current filing · view on EDGAR →

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.

The company scheduled its first quarter 2026 earnings release for after market close on May 5, 2026. This is a routine quarterly earnings announcement with no financial results disclosed in this filing.

Added Conference call details low

Added in current filing · view on EDGAR →

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to discuss these results.

Management will host a conference call and webcast on May 5, 2026 at 4:30 p.m. ET to discuss the quarterly results. This is standard practice for earnings announcements.

Event · Item 2.02 — Results of Operations and Financial Condition

~100 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added
Show 1 minor / wording change
Added Q1 2026 earnings announcement date low

Added in current filing · verify on EDGAR →

Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026. The Company will host a conference call and webcast on Tuesday, May 5, 2026 at 4:30 p.m. E.T. to discuss its first quarter 2026 financial and business results.

The company disclosed it will release Q1 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day. This is a routine scheduling announcement informing investors when to expect quarterly results.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 19, 2026 · How we verify